Navigation Links
Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
Date:11/10/2011

CRANBURY, N.J., Nov. 10, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) will announce its first quarter, fiscal year 2012 financial results on Tuesday, November 15, 2011 before the open of the U.S. financial markets.

Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on November 15, 2011, which will include discussion of the results of operations in greater detail and an update on corporate developments.Schedule for the Financial Results Press Release, Conference Call / Webcast-
Q1 Fiscal Year 2012 Financial Results Press Release11/15/2011 at 7:30 a.m. ET-
Q1 Fiscal Year 2012 Conference Call-Live

11/15/2011 at 11:00 a.m. ETDomestic Dial-In Number

1-888-256-1007International Dial-In Number

1-913-312-1466Pass code

3249586-
Q1 Fiscal Year 2012 Conference Call-Replay

11/15-11/22/2011Domestic Dial-In Number

1-888-203-1112International Dial-In Number

1-719-457-0820Pass code

3249586-
Webcast Live and Replay Access

http://www.palatin.comThe webcast and replay can be accessed by logging on to the "Investor/Media Center-Webcasts"

section of Palatin's website at http://www.palatin.comAbout Palatin Technologies, Inc.Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.  For additional information regarding Palatin, please visit Palatin's website at www.palatin.com.

Palatin Technologies Investor Inquiries:Palatin Technologies Media Inquiries:Stephen T. Wills, CPA, MST

Carney Noensie, Burns McClellanChief Operating Officer / Chief Financial OfficerVice President, Investor RelationsTel: (609) 495-2200 / info@palatin.com

Tel: (212) 213-0006 / cnoensie@burnsmc.com
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Palatin Technologies to Present at 10th Annual BIO Investor Forum
2. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2011 Results
3. Palatin Technologies, Inc. to Report Fiscal Year 2011 Fourth Quarter Results; Teleconference and Webcast to be held on September 22, 2011
4. Palatin Technologies, Inc. to Present at the Rodman & Renshaw Annual Global Investment Conference
5. Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca
6. Palatin Technologies, Inc. Announces Presentation and Publication on Validation of Scale for Subjective Male Sexual Arousal
7. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results
8. Palatin Technologies, Inc. Announces Results of Annual Stockholders Meeting
9. Palatin Technologies, Inc. to Present at the ROTH 23rd Annual OC Growth Stock Conference
10. Palatin Technologies, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
11. Palatin Technologies, Inc. Announces Proposed Public Offering of Common Stock and Warrants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)...  The Biodesign Challenge (BDC), a university competition that ... living systems and biotechnology, announced its winning teams at ... New York City . The teams, ... at MoMA,s Celeste Bartos Theater during the daylong summit. ... curator of architecture and design, and Suzanne Lee ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® ... provides a free webinar on Performing Quality Investigations: Getting to Root ... CT at no charge. , Incomplete investigations are still a major concern to ...
Breaking Biology Technology:
(Date:5/24/2016)... superior patient care by providing unparalleled technology to leaders of the medical imaging industry. ... recently added to the range of products distributed by Ampronix. Photo - ... ... ... ...
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour ... from the Q1 wave of its quarterly wearables survey. ... receptivity to a program where they would receive discounts ... company. "We were surprised to see that ... LaColla , CEO of Troubadour Research, "primarily because there ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
Breaking Biology News(10 mins):